ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

Drugs & Targets

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

Clinical Roundup

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

April 26, 2024

Vol.50 No.17

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

YOU MAY BE INTERESTED IN

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Renew today!

Subscriber content

Login

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

YOU MAY BE INTERESTED IN

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Login

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence